Amgen Inc. $AMGN Stock Acquired by Leuthold Group LLC

Leuthold Group LLC increased its stake in Amgen Inc. (NASDAQ:AMGN) by 9.2% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 22,409 shares of the medical research company’s stock after acquiring an additional 1,897 shares during the period. Leuthold Group LLC’s holdings in Amgen were worth $9,446,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of AMGN. Fulcrum Asset Management LLP increased its holdings in shares of Amgen by 65.5% during the 3rd quarter. Fulcrum Asset Management LLP now owns 4,428 shares of the medical research company’s stock worth $1,876,000 after buying an additional 1,752 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its holdings in Amgen by 16.9% in the third quarter. Allspring Global Investments Holdings LLC now owns 112,799 shares of the medical research company’s stock valued at $45,940,000 after acquiring an additional 16,327 shares during the last quarter. Beverly Hills Private Wealth LLC boosted its holdings in Amgen by 2.6% in the third quarter. Beverly Hills Private Wealth LLC now owns 2,399 shares of the medical research company’s stock valued at $1,011,000 after acquiring an additional 60 shares during the last quarter. Almanack Investment Partners LLC. grew its position in Amgen by 7.5% during the third quarter. Almanack Investment Partners LLC. now owns 2,553 shares of the medical research company’s stock valued at $1,076,000 after acquiring an additional 178 shares during the period. Finally, M Holdings Securities Inc. purchased a new stake in Amgen during the third quarter valued at about $1,584,000. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: New AHA 2026 data reinforced Repatha’s potential: an analysis found it cost-effective for high-risk patients without a prior heart attack or stroke, while a separate long-term analysis associated treatment with a 29% lower risk of major cardiovascular events in patients with ASCVD. The findings could support wider use, though the reported analyses do not guarantee future sales growth. Article: New Repatha data at AHA 2026
• Positive Sentiment: Amgen is heading into ACR week with a dazodalibep update expected November 11, creating a near-term clinical catalyst for its pipeline. The article headline does not specify the results, so the update’s impact will depend on the data. Article: Amgen stock heads into ACR week with dazodalibep update
• Positive Sentiment: An article highlighted experimental obesity drug MariTide’s potential to reduce dosing from 52 injections a year to four. If borne out in clinical development, less frequent dosing could be a competitive advantage; the drug remains experimental. Article: Amgen’s new drug could mean fewer shots for obesity patients
• Neutral Sentiment: Amgen shares rose in Monday trading but underperformed the broader market, indicating the move was not as strong as the overall market’s. Article: Amgen stock rises Monday, still underperforms market
• Negative Sentiment: ETFs were net sellers of $68.5 million of AMGN on November 5, a potential near-term supply headwind, although 51 funds bought shares and 20 sold. Article: ETFs are net sellers of Amgen

Analysts Set New Price Targets

AMGN has been the subject of several research analyst reports. Morgan Stanley upped their price target on Amgen from $359.00 to $410.00 and gave the stock an “equal weight” rating in a research note on Wednesday, November 4th. Barclays lifted their price objective on Amgen from $380.00 to $400.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 21st. BMO Capital Markets decreased their target price on Amgen from $450.00 to $415.00 and set a “market perform” rating for the company in a report on Monday, October 12th. HSBC cut Amgen from a “buy” rating to a “hold” rating and decreased their target price for the stock from $445.00 to $425.00 in a report on Thursday, September 10th. Finally, Canaccord Genuity Group raised their price target on shares of Amgen from $384.00 to $440.00 and gave the company a “hold” rating in a report on Wednesday, November 4th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, eighteen have assigned a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $422.76.

Insider Activity

In related news, SVP Rachna Khosla sold 1,252 shares of the firm’s stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $416.43, for a total transaction of $521,370.36. Following the sale, the senior vice president directly owned 6,404 shares in the company, valued at approximately $2,666,817.72. This trade represents a 16.35% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 0.85% of the company’s stock.

Amgen Stock Up 1.0%

Shares of Amgen stock opened at $465.23 on Tuesday. The company has a fifty day moving average price of $423.08 and a 200 day moving average price of $378.80. The company has a current ratio of 1.48, a quick ratio of 1.13 and a debt-to-equity ratio of 3.60. Amgen Inc. has a twelve month low of $312.39 and a twelve month high of $483.99. The stock has a market cap of $251.52 billion, a price-to-earnings ratio of 26.99, a price-to-earnings-growth ratio of 3.47 and a beta of 0.43.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.79 by $0.66. Amgen had a return on equity of 114.99% and a net margin of 24.14%. The firm had revenue of $10.37 billion during the quarter, compared to the consensus estimate of $10.07 billion. During the same period in the prior year, the firm earned $5.64 EPS. The firm’s quarterly revenue was up 8.5% compared to the same quarter last year. Equities research analysts forecast that Amgen Inc. will post 23.33 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, December 11th. Stockholders of record on Friday, November 20th will be paid a $2.52 dividend. The ex-dividend date is Friday, November 20th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.2%. Amgen’s dividend payout ratio (DPR) is 58.47%.

Amgen Profile

Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases.

The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally.

Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A.